Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018

SMi Group13 - 14 June 2018, London, UK.
Although an old process, pharmaceutical freeze drying is ever evolving with new trends and approaches being used for pharmaceutical formulation. In it's 6th year, the conference will cover the most recent advances in Freeze drying technology and discuss the latest ideas in the industry. It is the perfect platform to strengthen knowledge in key principles such as PAT and QbD, whilst staying at the forefront of technological breakthroughs to adapt to growing manufacturing demands.

Gathering a room of Senior Scientists and Heads of Pharmaceutical Engineering, the 6th annual show provides an ideal forum to discuss the latest advancements in pharmaceutical lyophilisation, welcoming regulatory guidance from the NIBSC-MHRA and expertise from the likes of Sanofi, Boehringer Ingelheim, Janssen, GSK and more.

Network & Benefit From Industry Experts:

  • [CHAIR] SuneKlint Anderson, Principal Scientist, Janssen
  • Paul Matejtschuk, Principal Scientist, NIBSC - MHRA
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • ErwanBourles, Expert Scientist, Head Filling Drying Device, GlaxoSmithKline
  • MiguelaVieru, Senior Scientist, Janssen
  • Eric Munson, Patrick Deluca Endowed Professor of Pharmaceutical Technology, University of Kentucky
  • Patrick Garidel, Bioprocess and Pharmaceutical Development Biologicals, Boehringer Ingelheim
  • Daryl Williams, Reader in Particle Science, Imperial College London

Featured Highlights this June:

  • Discuss the use of old and new methods in terms of the optimisation of freeze drying cycles
  • Learn about case studies which delve into the processes through which cycles can be refined to the utmost efficiency
  • Hear about a new PAT for freeze drying cycle development through vial impedance spectroscopy
  • Discover ways in which water activity measurement and mathematical modelling can be used to evaluate the stability of freeze dried vaccines
  • Evaluate quality-by-design strategies, applied to spray drying, versus lyophilisation

Don't forget to check out the two-post conference interactive workshops taking place on 12th June.

For those looking to attend there are early-bird rates currently available of up to £400.

Further information is available at: www.pharmafreezedrying.com/wpn

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...